BioSpace News Archive

Zentalis™ Pharmaceuticals, Inc. today announced the appointment of Carrie Brownstein, MD, as Chief Medical Officer (CMO), effective October 3, 2022.

MiMedx Group, Inc. today announced the launch of AMNIOEFFECT™, a tri-layer PURION® processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.

Zealand Pharma A/S announced that clinical results from the two-part Phase 3 trial of dasiglucagon for the treatment of congenital hyperinsulinism in newborns and infants up to 12 months of age were presented at the 60th annual European Society for Paediatric Endocrinology meeting, held in Rome, September 15-17, 2022.

23andMe Holding Co., a leading consumer genetics and research company, appointed Daniel Chu as Chief Product Officer.

BeiGene Receives Positive CHMP Opinion for BRUKINSA ® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma.

AnPac Bio-Medical Science Co., Ltd. announced that on September 16, 2022, the Company filed a request for a hearing before the NASDAQ Hearings Panel to present its financial data including Shareholders’ Equity and plan with the applicable listing requirements.

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, and Providence, a not-for-profit health system serving the Western U.S., today announced a multi-system, national contract to acquire AquaBeam Robotic Systems.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), announced today that it has signed an exclusive global commercial partnership agreement with Verséa Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), one of the fastest growing U.S. healthcare companies, specialized in the sale and distribution of ocular diagnostic and therapeutic solutions.

The Muscular Dystrophy Association announced today the awarding of 70 new grants totaling over $17 million toward neuromuscular disease research.

TB Alliance welcomes Kim Schwartz and Rasha Hibri to its Board of Directors. Their expertise will help guide the organization as it continues to advance its research and product delivery agenda.